Sino Biopharmaceutical Ltd 2018 SR
The report covers the 2018 fiscal year, highlighting Sino Biopharmaceutical's commitment to R&D innovation and sustainable development. Key achievements include the launch of the oncology drug Anlotinib and the implementation of intelligent production lines. The company focused on environmental protection through energy-saving refurbishments and waste reduction initiatives. Socially, it emphasized employee development, health and safety, and community contributions, particularly in hepatitis prevention and postoperative rehabilitation (ERAS).
Company: Sino Biopharmaceutical Ltd
Sector: Manufacturing
Country: Hong Kong
Year: 2018
Type: SR
Pages: 30
Back to company
Sino Biopharmaceutical Ltd
ESG Report
The report covers the 2018 fiscal year, highlighting Sino Biopharmaceutical's commitment to R&D innovation and sustainable development. Key achievements include the launch of the oncology drug Anlotinib and the implementation of intelligent production lines. The company focused on environmental protection through energy-saving refurbishments and waste reduction initiatives. Socially, it emphasized employee development, health and safety, and community contributions, particularly in hepatitis prevention and postoperative rehabilitation (ERAS).
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Employees